Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

NCT06780111 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

298

Enrollment

INDUSTRY

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

BIOLOGICAL: Pembrolizumab
BIOLOGICAL: I-DXd
DRUG: Leucovorin
DRUG: Levoleucovorin
DRUG: 5-Fluorouracil (5-FU)
DRUG: Oxaliplatin
BIOLOGICAL: Sacituzumab tirumotecan
DRUG: Rescue Medication

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]